Mitochondrial oxidative phosphorylation disorder due to a point mutation of mitochondrial DNA

Mitochondrial oxidative phosphorylation (OXPHOS) disorder due to a point mutation of mitochondrial DNA encompasses a broad group of rare genetic conditions in which a single nucleotide change in the mitochondrial genome disrupts the function of the electron transport chain and ATP synthesis. The mitochondrial respiratory chain, composed of complexes I through V, is responsible for generating the majority of cellular energy. Point mutations in mitochondrial DNA (mtDNA) can affect genes encoding transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), or protein subunits of the respiratory chain complexes, leading to impaired energy production in affected tissues. Well-known clinical entities falling under this umbrella include MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), MERRF (myoclonic epilepsy with ragged red fibers), NARP (neuropathy, ataxia, and retinitis pigmentosa), and Leber hereditary optic neuropathy (LHON), among others. Because mitochondria are present in virtually all cells, these disorders can affect multiple organ systems, with a predilection for tissues with high energy demands. Commonly affected systems include the central and peripheral nervous system, skeletal muscle, heart, eyes, ears, kidneys, and endocrine organs. Key clinical features vary widely depending on the specific mutation, the degree of heteroplasmy (the proportion of mutant versus normal mtDNA), and tissue distribution, but frequently include exercise intolerance, muscle weakness (myopathy), seizures, stroke-like episodes, sensorineural hearing loss, optic atrophy or visual impairment, cardiomyopathy, diabetes mellitus, lactic acidosis, and developmental regression or intellectual disability. Onset can range from infancy to adulthood. There is currently no cure for mitochondrial OXPHOS disorders due to mtDNA point mutations. Management is largely supportive and symptomatic, including nutritional supplementation with coenzyme Q10, L-carnitine, B vitamins, and other cofactors, though evidence for their efficacy remains limited. Seizure management, cardiac monitoring, endocrine management, physical therapy, and multidisciplinary care are essential components of treatment. Genetic counseling is important given the maternal inheritance pattern and the complexities of heteroplasmy in predicting disease severity and recurrence risk.

Common questions about Mitochondrial oxidative phosphorylation disorder due to a point mutation of mitochondrial DNA